Advertisement

Molecular Neurobiology

, Volume 41, Issue 2–3, pp 290–298 | Cite as

A Hapten Generated from an Oxidation Fragment of Docosahexaenoic Acid Is Sufficient to Initiate Age-Related Macular Degeneration

  • Joe G. HollyfieldEmail author
  • Victor L. Perez
  • Robert G. Salomon
Article

Abstract

The protein adduct carboxyethylpyrrole (CEP) is present in age-related macular degeneration (AMD) eye tissue and in the blood of AMD patients at higher levels than found in age-matched non-AMD tissues. Autoantibodies to CEP are also higher in AMD blood samples than in controls. To test the hypothesis that this hapten is causally involved in initiating an inflammatory response in AMD, we immunized C57BL/6J mice with mouse serum albumin (MSA) adducted with CEP. Immunized mice develop antibodies to CEP, fix complement component-3 in Bruch’s membrane, accumulate drusen below the retinal pigment epithelium during aging, show decreased a- and b-wave amplitudes in response to light, and develop lesions in the retinal pigment epithelium mimicking geographic atrophy, the blinding end-stage condition characteristic of the dry form of AMD. Inflammatory cells are present in the region of lesions and may be actively involved in the pathology observed. We conclude that early immunization of mice with CEP-adducted MSA sensitizes these animals to the ongoing production of CEP adducts in the outer retina where DHA is abundant and the conditions for oxidative damage are permissive. In response to this early sensitization, the immune system mounts a complement-mediated attack on the cells of the outer retina where CEP adducts are formed. This animal model for AMD is the first that was developed from an inflammatory signal discovered in eye tissue and blood from AMD patients. It provides a novel opportunity for dissecting the early pathology of AMD and the immune response contributing to this disorder. The availability of a mouse with a mechanistically based AMD-like disease that progresses rapidly is highly desirable. Such a model will allow for the efficient preclinical testing of the much-needed therapeutics quickly and inexpensively.

Keyword

Inflammation Retina Oxidative damage Age-related macular degeneration Fatty acid 

Notes

Acknowledgements

Supported by the State of Ohio BRTT Program, Columbus, Ohio; a Research Center Grant from the Foundation Fighting Blindness, Owings Mills, Maryland; a Challenge Grant from Research to Prevent Blindness, New York, NY; and by grants from the National Institutes of Health, Bethesda, Maryland, [EY014240 (JGH), EY015638 (JGH), EY014912 (VLP), and GM21249 (RGS)]. We thank Xiaoping (Annie) Yang, Mary E. Rayborn, Karen G. Shadrach, Vera L. Bonilha, and Yong Li for their help with the microscopy and immunology performed in these studies. We also thank Lisa Kuttner-Kondo, John W. Crabb, Bela Anand-Apte, and Neal S. Peachey for discussions and valuable comments during the course of these studies.

References

  1. 1.
    Javitt JC, Zhou Z, Maguire MG, Fine SL, Willke RJ (2003) Ophthalmol 110:1534–1539CrossRefGoogle Scholar
  2. 2.
    Augood C, Vingerling JR, de Jong PT, Chakravarthy U, Seland J, Soubrane G, Tomazzoli L, Topouzis F, Bentham G, Rahu M, Vioque J, Young IS, Fletcher AE (2006) Arch Ophthalmol 124:529–535CrossRefPubMedGoogle Scholar
  3. 3.
    Curcio C, Millican C, Bailey T, Kruth H (2001) Invest Ophthalmol Vis Sci 42:265–274PubMedGoogle Scholar
  4. 4.
    Hussain A, Rowe L, Marshall J (2002) J Opt Soc Am A Opt Image Sci Vis 19:166–172CrossRefPubMedGoogle Scholar
  5. 5.
    Moore D, Hussain A, Marshall J (1995) Invest Ophthalmol Vis Sci 36:1290–1297PubMedGoogle Scholar
  6. 6.
    Bressler SB, Maguire MG, Bressler NM, Fine SL (1990) Arch Ophthalmol 108:1442–1447PubMedGoogle Scholar
  7. 7.
    Sarks SH, van Driel D, Maxwell L, Killingsworth M (1980) Trans Ophthalmol Soc UK 100:414–422PubMedGoogle Scholar
  8. 8.
    Vinding T (1990) Acta Ophthalmol 68:410–414CrossRefGoogle Scholar
  9. 9.
    Holz FG, Bellman C, Staudt S, Schutt F, Volcker HE (2001) Invest Ophthalmol Vis Sci 42:1051–1056PubMedGoogle Scholar
  10. 10.
    Hollyfield JG, Crabb JW, Salomon RG (2003) Adv Exp Med Biol 533:83–89PubMedGoogle Scholar
  11. 11.
    Crabb JW, Miyagi M, Gu X, Shadrach KG, West KA, Sakaguchi H, Kamei M, Hasan A, Yan L, Rayborn ME, Salomon RG, Hollyfield JG (2002) Proc Natl Acad Sci USA 99:14682–14687CrossRefPubMedGoogle Scholar
  12. 12.
    Sakaguchi H, Miyagi M, Shadrach KG, Rayborn ME, Crabb JW, Hollyfield JG (2002) Exp Eye Res 74:547–549CrossRefPubMedGoogle Scholar
  13. 13.
    Bando H, Shadrach KG, Rayborn ME, Crabb JW, Hollyfield JG (2007) Exp Eye Res 84:135–142CrossRefPubMedGoogle Scholar
  14. 14.
    Rayborn ME, Sakaguchi H, Shadrach KG, Crabb JS, Crabb JW, Hollyfield JG (2006) Adv Exp Med Biol 572:75–78CrossRefPubMedGoogle Scholar
  15. 15.
    Nakata K, Crabb JW, Hollyfield JG (2005) Exp Eye Res 80:821–826CrossRefPubMedGoogle Scholar
  16. 16.
    Johnson LV, Leitner WP, Staples MK, Anderson DH (2001) Exp Eye Res 73:887–896CrossRefPubMedGoogle Scholar
  17. 17.
    Hageman GS, Mullins RF (1999) Mol Vis 5:28–37PubMedGoogle Scholar
  18. 18.
    Anderson DH, Mullins RF, Hageman GS, Johnson LV (2002) Am J Ophthalmol 134:411–431CrossRefPubMedGoogle Scholar
  19. 19.
    Hageman GS, Luthert PJ, Chong NH, Johnson LV, Anderson DH, Mullins RF (2001) Prog Retina Eye Res 20:705–732CrossRefGoogle Scholar
  20. 20.
    Johnson LV, Ozaki S, Staples ML, Erickson PA, Anderson DH (2000) Exp Eye Res 70:441–449CrossRefPubMedGoogle Scholar
  21. 21.
    Doyne RW (1989) Trans Ophthalmol Soc U K 19:71–71Google Scholar
  22. 22.
    Gass JDM (1987) Stereoscopic atlas of macular diseases. CV Mosby, St. LouisGoogle Scholar
  23. 23.
    Meyers SM, Zachary AA (1988) Arch Ophthalmol 106:651–653PubMedGoogle Scholar
  24. 24.
    Seddon JM, Ajani UA, Mitchell BD (1997) Am J Ophthalmol 123:199–206PubMedGoogle Scholar
  25. 25.
    Klein RJ, Zeiss C, Chew EY, Tsai JY, Sackler RS, Haynes C, Henning AK, SanGiovanni JP, Mane SM, Mayne ST, Bracken MB, Ferris F, Ott J, Barnstable C, Hoh J (2005) Science 308:385–389CrossRefPubMedGoogle Scholar
  26. 26.
    Edwards AO, Ritter R, Abel KJ, Manning A, Panhuysen C, Farrer LA (2005) Science 308:421–424CrossRefPubMedGoogle Scholar
  27. 27.
    Hageman GS, Anderson DH, Johnson LV, Hancox LS, Taiber AJ, Hardisty LI, Hageman JL, Stockman HA, Borchardt JD, Gehrs KM, Smith RJ, Silvestri G, Russell SR, Klaver CC, Barbazetto I, Chang G, Yannuzzi LA, Barile GR, Merriam JC, Smith RT, Olsh AK, Bergeron J, Zernant J, Merriam JE, Gold B, Dean M, Allikmets R (2005) Proc Natl Acad Sci U S A 102:7227–7232CrossRefPubMedGoogle Scholar
  28. 28.
    Haines JL, Hauser MA, Schmidt S, Scott WK, Olson LM, Gallins P, Spencer KL, Kwan SY, Noureddine M, Gilbert JR, Schnetz-Boutaud N, Agarwal A, Postel EA, Pericak-Vance MA (2005) Science 308:419–421CrossRefPubMedGoogle Scholar
  29. 29.
    Gold B, Merriam JE, Zernant J, Hancox LS, Taiber AJ, Gehrs KM, Cramer K, Neel J, Bergeron J, Barile GR, Smith RT, Group AGCS, Hageman GS, Dean M, Allikmets R (2006) Nature Genet 38:458–462CrossRefPubMedGoogle Scholar
  30. 30.
    Gu X, Meer SG, Miyagi M, Rayborn ME, Hollyfield JG, Crabb JW, Salomon RG (2003) J Biol Chem 278:42027–42035CrossRefPubMedGoogle Scholar
  31. 31.
    Seddon JM, Willett WC, Speizer FE, Hankinson SE (1996) J Am Med Assoc 276:1141–1146CrossRefGoogle Scholar
  32. 32.
    Klein RJ, Klein BE, Cruickshanks KJ (1999) Prog Retin Eye Res 18:371–389CrossRefPubMedGoogle Scholar
  33. 33.
    Snow K, Seddon JM (1999) Ophthalmic Epidemiol 6:125–143CrossRefPubMedGoogle Scholar
  34. 34.
    Christen WG, Glynn RJ, Manson JE, Ajani UA, Buring JE (1996) JAMA 276:1147–1151CrossRefPubMedGoogle Scholar
  35. 35.
    Smith W, Mitchell P, Leeder SR (1996) Arch Ophthalmol 114:1518–1523PubMedGoogle Scholar
  36. 36.
    Solberg Y, Rosner M, Belkin M (1998) Surv Ophthalmol 42:535–547CrossRefPubMedGoogle Scholar
  37. 37.
    AREDS RG (2001) Arch Ophthalmol 119:1439–1452Google Scholar
  38. 38.
    Fliesler SJ, Anderson RE (1983) Prog Lipid Res 22:79–131CrossRefPubMedGoogle Scholar
  39. 39.
    Anderson RE, Lissandrello PM, Maude MB, Matthes MT (1976) Exp Eye Res 23:149–157CrossRefPubMedGoogle Scholar
  40. 40.
    Kaur K, Salomon RG, O’Neil J, Hoff H (1997) Chem Res Toxicol 10:1387–1396CrossRefPubMedGoogle Scholar
  41. 41.
    Gu X, Sun M, Hazen SL, Crabb JW, Salomon RG (2003) J Org Chem 68:3749–3761CrossRefPubMedGoogle Scholar
  42. 42.
    Hollyfield JG, Bonilha VL, Lu L, Rayborn ME, Yang X, Shadrach KG, Ufret RL, Salomon RG, Perez VL (2008) Nat Med 14:194–198CrossRefPubMedGoogle Scholar
  43. 43.
    Peakman M, Senaldi G, Vergan D (1989) J Clin Pathol 42:1018–1025CrossRefPubMedGoogle Scholar
  44. 44.
    Mombaerts P, Iacomini J, Johnson R, Herrup K, Tonegawa S, Papaioannou V (1992) Cell 68:869–877CrossRefPubMedGoogle Scholar
  45. 45.
    Anderson RE (1970) Exp Eye Res 10:339–344CrossRefPubMedGoogle Scholar
  46. 46.
    LaVail MM (1976) Exp Eye Res 23:277–280CrossRefPubMedGoogle Scholar
  47. 47.
    Besharse JC, Hollyfield JG (1979) Invest Ophthalmol Vis Sci 18:1019–1024PubMedGoogle Scholar
  48. 48.
    Gordon W, Rodriguez de Turco E, Bazan N (1992) Curr Eye Res 11:73–83CrossRefPubMedGoogle Scholar
  49. 49.
    Rodriguez de Turco E, Parkins N, Ershov A, Bazan N (1999) J Neurosci Res 57:479–486CrossRefPubMedGoogle Scholar
  50. 50.
    Sun M, Finnemann S, Febbraio M, Shan L, Annangudi S, Podrez E, Hoppe G, Darrow R, Organisciak D, Salomon R, Silverstein R, Hazen S (2006) J Biol Chem 281:4222–4230CrossRefPubMedGoogle Scholar
  51. 51.
    Salomon R, Subbanagounder G, Singh U, O’Neil J, Hoff H (1997) Chem Res Toxicol 10:750–759CrossRefPubMedGoogle Scholar
  52. 52.
    Brame C, Boutaud O, Davies S, Yang T, Oates J, Roden D, Roberts L 2nd (2004) J Biol Chem 279:13447–13451CrossRefPubMedGoogle Scholar
  53. 53.
    Goyal J, Wang K, Liu M, Subbaiah P (1997) J Biol Chem 272:16231–16239CrossRefPubMedGoogle Scholar
  54. 54.
    Ambati J, Anand A, Fernandez S, Sakurai E, Lynn B, Kuziel W, Rollins B, Ambati B (2003) Nature Med 9:1390–1397CrossRefPubMedGoogle Scholar
  55. 55.
    Gottsch J, Bynoe L, Harlan J, Rencs E, Green W (1993) Arch Ophthalmol 111:126–129PubMedGoogle Scholar
  56. 56.
    Cousins S, Espinosa-Heidmann D, Alexandridou A, Sall J, Dubovy S, Csaky K (2002) Exp Eye Res 75:543–553CrossRefPubMedGoogle Scholar
  57. 57.
    Malek G, Johnson L, Mace B, Saloupis P, Schmechel D, Rickman D, Toth C, Sullivan P (2005) Proc Natl Acad Sci U S A 102:11900–11905CrossRefPubMedGoogle Scholar
  58. 58.
    Fox G, Kuwabara T, Wiggert B, Redmond T, Hess H, Chader G, Gery I (1987) Clin Immunol Immunopathol 43:256–264CrossRefPubMedGoogle Scholar
  59. 59.
    Hirose S, Wiggert B, Redmond M, Kuwabara T, Nussenblatt R, Chader G, Gery I (1987) Exp Eye Res 45:695–702CrossRefPubMedGoogle Scholar
  60. 60.
    de Kozak Y, Verwaerde C (2002) Int Rev Immunol 21:231–253CrossRefPubMedGoogle Scholar
  61. 61.
    Caspi R, Chan C, Leake W, Higuchi M, Wiggert B, Chader G (1990) J Autoimmun 3:237–246CrossRefPubMedGoogle Scholar
  62. 62.
    Caspi R (2003) Immunol Res 27:149–160CrossRefPubMedGoogle Scholar
  63. 63.
    Nussenblatt R (2002) Int Rev Immunol 21:273–289CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  • Joe G. Hollyfield
    • 1
  • Victor L. Perez
    • 2
  • Robert G. Salomon
    • 3
  1. 1.Cole Eye InstituteCleveland Clinic Lerner College of MedicineClevelandUSA
  2. 2.Bascom-Palmer Eye InstituteUniversity of Miami School of MedicineMiamiUSA
  3. 3.Department of ChemistryCase Western Reserve UniversityClevelandUSA

Personalised recommendations